Basf Pharma Belgium SA
Basf Pharma Belgium reported total assets of €11.6m at the end of the 2025 financial year (annual accounts filed with the NBB on 28 May 2026).
The score of Basf Pharma Belgium shows with a free account.
See the score- Summary? / 5
- Balance sheet strength
- Liquidity
- Repayment capacity
- Profitability
- Trajectory
- Compliance and register
- Position in its sectorvs peers
- Supplier creditat 30 d
- Borrowing capacityborrowable
- Valuationcentral
Visible once signed in: create your account, the 14-day Pro trial is free.
Key figures 2025
Change 2022 → 2025: Equity +8 % Total assets +8 %
Accounts of the company itself (not consolidated).
The full file covers 10 financial years; a free account shows 2. →Deterministic calculation on the filed accounts, no AI. Dispute the score or report an error
Basf Pharma Belgium's annual accounts
Filed annual accounts
- Year ended 31 Dec 2025filed on 28 May 2026
- Year ended 31 Dec 2024filed on 05 May 2025
- Year ended 31 Dec 2023filed on 13 May 2024
- Year ended 31 Dec 2022filed on 04 May 2023
- Year ended 31 Dec 2021filed on 02 Jun 2022
Basf Pharma Belgium's financial analysis
- Solvency99.8%sector median: 49.3%
- Current ratio
- Net margin
- ROE
- Financial debt / EBITDA
- Interest coverage
- Days sales outstanding (DSO)
Management and control of Basf Pharma Belgium
Basf Pharma Belgium's publications in the Belgian Gazette
Company number, VAT number and registered office
- Company number (CBE)
- 0845.445.466
- VAT number
- BE0845445466
- Peppol
- Not found on Peppol as of 10 Nov 2026 · Check
- Legal form
- SA
- Incorporated
- 23 Apr 2012
- Registered office
- 2040 Antwerp
- Latest accounts
- 2025 · filed on 28 May 2026
- Activity
- Manufacture of other organic basic chemicals (NACE 20140)
Basf Pharma Belgium (SA) has been based in Antwerp since 2012, active in: manufacture of other organic basic chemicals. For 2025, it reports a net profit of 183,245 € and equity of €11.6m; its revenue is not published. Its solvency stands at 99.8%, above the median of its sector (49.3%).
Companies similar to Basf Pharma Belgium
Companies in the same business, of comparable size and area, outside its group.
- B.C. Oncology Research and experimental development on natural sciences and engineering Zaventem · balance sheet €9.50m
- Everlam Holding Manufacture of plastic plates, sheets, tubes and profiles Mechelen · balance sheet €13.0m
- Intrexon Actobiotics Research and experimental development on natural sciences and engineering Nazareth-De Pinte · balance sheet €8.76m
- The Akkermansia Company Research and experimental development on natural sciences and engineering Mont-Saint-Guibert · balance sheet €16.9m
- XpressBioX Manufacture of basic pharmaceutical products Herstal · balance sheet €8.92m
- ATB Therapeutics Manufacture of basic pharmaceutical products Marche-en-Famenne · balance sheet €10.6m
- 4Tissue Manufacture of medical and dental instruments and supplies Ghent · balance sheet €2.56m
- Tessenderlo Chemie International Activities of head offices Ixelles · balance sheet €25.5m
Frequently asked questions about Basf Pharma Belgium
What is the revenue of Basf Pharma Belgium?
Basf Pharma Belgium files its accounts in a format where revenue is optional: it is not published for 2025.
What is the VAT number of Basf Pharma Belgium?
In Belgium, the VAT number is the company number prefixed with BE: BE0845445466 for Basf Pharma Belgium, if the company is VAT-registered. Its company number (CBE) is 0845.445.466.
Where is the registered office of Basf Pharma Belgium?
According to the CBE register, the registered office of Basf Pharma Belgium is in 2040 Antwerp.
What is the equity of Basf Pharma Belgium?
At the close of the 2025 financial year, the equity of Basf Pharma Belgium amounts to 11,628,201 €, a solvency of 99.8% of total assets.
Who manages Basf Pharma Belgium?
The register lists 2 active mandates at Basf Pharma Belgium. Names and roles are in the full file, with the deeds published in the Belgian Gazette.
The full file of Basf Pharma Belgium
Directors and mandates, ownership network, Gazette deeds, ten years of accounts and ratios, Excel export, and Idonis's analysis in one question.
Open the full file →